The estimated Net Worth of Timothy P Walbert is at least $197 Milión dollars as of 4 January 2023. Mr. Walbert owns over 219,995 units of Horizon Therapeutics Plc stock worth over $83,032,850 and over the last 14 years he sold HZNP stock worth over $100,349,019. In addition, he makes $13,873,200 as Chairman of the Board, President a Chief Executive Officer at Horizon Therapeutics Plc.
Timothy has made over 62 trades of the Horizon Therapeutics Plc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 219,995 units of HZNP stock worth $25,585,419 on 4 January 2023.
The largest trade he's ever made was exercising 408,347 units of Horizon Therapeutics Plc stock on 14 November 2018 worth over $2,907,431. On average, Timothy trades about 35,625 units every 33 days since 2010. As of 4 January 2023 he still owns at least 713,954 units of Horizon Therapeutics Plc stock.
You can see the complete history of Mr. Walbert stock trades at the bottom of the page.
Timothy P. Walbert is Chairman of the Board, President, Chief Executive Officer of the Company. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, Mr. Walbert served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert serves as the chairman of the board of directors of Zyla Life Sciences, a public pharmaceutical company, and is also a member of the board of directors of Exicure, Inc., a public clinical-stage biotechnology company. He also sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO), the Biotechnology Innovation Organization (BIO), World Business Chicago (WBC) and the Greater Chicago Arthritis Foundation. Mr. Walbert is also a member of the Illinois Innovation Council, the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College.
As the Chairman of the Board, President a Chief Executive Officer of Horizon Therapeutics Plc, the total compensation of Timothy Walbert at Horizon Therapeutics Plc is $13,873,200. There are no executives at Horizon Therapeutics Plc getting paid more.
Timothy Walbert is 53, he's been the Chairman of the Board, President a Chief Executive Officer of Horizon Therapeutics Plc since 2010. There are 14 older and 9 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.
Timothy's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY, CA, 94404.
Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F... a Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.
at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
Horizon Therapeutics Plc executives and other stock owners filed with the SEC include: